Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Daxdilimab in Active Proliferative Lupus Nephritis
2022-001377-31Phase 2Terminated
- Sponsor
- Horizon Therapeutics
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing Daxdilimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete Renal Response (CRR). Started Sep 2022; status: terminated.
02
Drugs
daxdilimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2022-001377-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001377-31.